On 26 November, the "Vi per Vida" charity organisation run by sommelier Xavi Ayala is holding a wine-tasting event for 400 people in Calella.
The proceeds of the event will go to IRB Barcelona, where advanced projects are being developed on metastasis, which causes 90% of deaths by cancer.
The initiative aims to raise 25,000 euros to fund the first year of a PhD student at IRB Barcelona.
The campaign is part of "Giving Tuesday", a day devoted to charitable donations, which this year falls on Tuesday 29 November.
He is awarded this prize for his work on colon cancer
This prestigious prize is given in recognition of molecular biology research performed by scientists working in Spain
To foster the next generation of scientific leaders, IRB Barcelona kicks off the international symposium series ENABLE, part of the Horizon 2020 Programme, for young researchers working in the Life Sciences.
Involving scientific debates, career sessions, and outreach activities, these 3-day symposia are jointly coordinated by young students from four European centres.
After first event in Barcelona in 2017, the ENABLE symposia will be held in Copenhagen in 2018, Nijmegen in 2019, and Milan in 2020.
Antonio Zorzano and Joan J. Guinovart are among the 34 projects awarded by the 2015 La Marató (telethon)
As of November, Núria López-Bigas, winner of the 2016 Banco Sabadell Foundation Prize for Biomedical Research, will join IRB Barcelona to continue her research on cancer using computational biology.
The Institute has also recruited Croatian scientist Fran Supek, who will launch his laboratory in 2017.
The biotech will set aside this injection of capital –led by Caixa Capital Risc- to complete the preclinical phase in order to start Human Phase I trials of its compound to the treatment of Cognitive Impairment Associated with Schizophrenia. The drug is one of the few under development worldwide to halt the progression and reverse the symptoms of this condition.
The drug is a first-in-class for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). The compound has been developed using their proprietary IPROTech, a cutting-edge platform the fast and cost-effectively obtaining of innovative drugs.
Iproteos, settled at the Parc Cientific de Barcelona, is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides, Teresa Tarragó and Ernest Giralt, based on the technology transfer from IRB Barcelona and the University of Barcelona.
The co-founder of IRB Barcelona and president of its External Advisory Board receives today, together with Manel Esteller and Josep Baselga, the Catalonia International Award presented by the Government of Catalonia.
Scientists from the US, Canada and Spain, among them Joan Guinovart from IRB Barcelona, are poised to perform joint research with the aim to find a treatment for Lafora disease, the most severe type of epilepsy in humans.
The National Health Institutes has awarded the consortium $8.5 over five years.
The US organisation Chelsea’s Hope, a charity formed by families affected by this disease, has promoted this international collaboration.
Miquel A. Pericàs, director of the Institute of Chemical Research of Catalonia (ICIQ), has taken over as general director of the Barcelona Institute of Science and Technology (BIST). He succeeds Montserrat Vendrell, the first director of the organization, who is moving on to take up an entrepreneurial post in the private sector.